Gilead Sciences, Inc. (FRA:GIS)
100.18
+0.71 (0.71%)
At close: Aug 22, 2025
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.08B USD in the quarter ending June 30, 2025, with 1.84% growth. This brings the company's revenue in the last twelve months to $28.86B, up 3.81% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.86B
Revenue Growth
+3.81%
P/S Ratio
4.94
Revenue / Employee
$1.64M
Employees
17,600
Market Cap
121.43B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Siemens Energy AG | 38.39B |
Rheinmetall AG | 10.67B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Gilead Sciences News
- 2 days ago - Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy - Benzinga
- 2 days ago - Gilead unit to acquire cell therapy developer Interius for $350 million - Reuters
- 2 days ago - Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug - Investor's Business Daily
- 2 days ago - Gilead's Kite buying Interius BioTherapeutics for $350M - Seeking Alpha
- 2 days ago - CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans - Benzinga
- 2 days ago - CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans - Benzinga
- 2 days ago - Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform - Business Wire
- 2 days ago - CVS Health reportedly excludes coverage for Gilead’s new HIV drug for now - Seeking Alpha